Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95122 | 0.79 | — | — | |
| SCHEMBL5144478 | 0.79 | ADORA2A (0.44) | ADORA2ADHFR | |
| SCHEMBL888386 | 0.79 | MGMT (0.30) | — | |
| SCHEMBL11362 | 0.70 | PI4KA (0.45) | ADORA2A | |
| SCHEMBL342514 | 0.70 | ALDH1A1 (0.44) | PDPK1GDA | |
| Hydrochloric Acid SCHEMBL14742344 | 0.68 | PI4KA (0.44) | ADORA2A | |
| SCHEMBL839587 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL1741651 | 0.68 | PI4KA (0.44) | ADORA2A | |
| Hydrochloric Acid SCHEMBL1741647 | 0.67 | ADORA2A (0.37) | ADORA2A | |
| SCHEMBL19236510 | 0.65 | CYP1A2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023071218-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 沈阳药科大学 | 2023-05-04 | — | — | WO | claimed |
| EP-3986568-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY | Storm Therapeutics Ltd (GB) | 2022-04-27 | — | — | EP | claimed |
| WO-2020254831-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY | STORM THERAPEUTICS LTD (GB) | 2020-12-24 | — | — | WO | claimed |
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | claimed |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-01-03 | — | — | US | claimed |
| EP-2271630-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-01-12 | — | — | EP | claimed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | claimed |
| EP-2091918-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-08-26 | — | — | EP | claimed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | claimed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | claimed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | claimed |
| US-20040203050-A1 | Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression | REICH NORBERT (US) | 2004-10-14 | — | — | US | claimed |
| US-20240294532-A1 | SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS | GALDERMA HOLDING S.A. (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-4370517-A1 | SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS | Galderma Holding SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-11708603-B2 | Normalization of polymerase activity | EXACT SCIENCES CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023071218-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 沈阳药科大学 | 2023-05-04 | — | — | WO | disclosed |
| EP-0034945-B1 | N-PHENYLPYRAZOLE DERIVATIVES | MAY & BAKER LIMITED (GB) | 1985-08-07 | — | — | EP | disclosed |
| US-4505740-A | Herbicidal 5-amino-4-cyano-1-phenyl-pyrazoles | MAY & BAKER LIMITED (GB) | 1985-03-19 | — | — | US | disclosed |
| US-4496390-A | WEED-CONTRTOLLING HERBICIDES | MAY & BAKER LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0034945-A2 | N-phenylpyrazole derivatives | MAY & BAKER LIMITED (GB) | 1981-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | PDPK1 66/4885GDA 3264/4885DCPS 4325/4885 |
| US-20240294532-A1 | SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS | MTOR, RICTOR, MLST8 | PDPK1 22/4885GDA 2334/4885DCPS 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.